Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price Up 3.8%

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) shares were up 3.8% during trading on Friday . The company traded as high as $1.77 and last traded at $1.76. Approximately 116,942 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 329,040 shares. The stock had previously closed at $1.70.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on MIST shares. Piper Sandler dropped their price target on Milestone Pharmaceuticals from $6.00 to $5.00 and set an "overweight" rating for the company in a research note on Tuesday, March 5th. HC Wainwright restated a "buy" rating and issued a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Friday, March 22nd. Finally, TD Cowen decreased their price target on Milestone Pharmaceuticals from $17.00 to $9.00 and set an "outperform" rating for the company in a report on Wednesday, December 27th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Milestone Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $11.20.

Milestone Pharmaceuticals Trading Up 3.8 %

The stock has a market cap of $93.54 million, a P/E ratio of -1.27 and a beta of 1.77. The firm's fifty day moving average price is $1.65 and its two-hundred day moving average price is $2.16. The company has a debt-to-equity ratio of 2.97, a current ratio of 10.11 and a quick ratio of 10.11.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its earnings results on Thursday, March 21st. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). As a group, equities research analysts forecast that Milestone Pharmaceuticals Inc. will post -1.15 EPS for the current year.

Institutional Trading of Milestone Pharmaceuticals

A number of institutional investors have recently modified their holdings of MIST. BlackRock Inc. raised its stake in Milestone Pharmaceuticals by 27.8% in the second quarter. BlackRock Inc. now owns 2,651,200 shares of the company's stock worth $7,556,000 after buying an additional 576,842 shares in the last quarter. Millennium Management LLC raised its stake in Milestone Pharmaceuticals by 5.4% in the second quarter. Millennium Management LLC now owns 1,358,362 shares of the company's stock worth $8,069,000 after buying an additional 69,439 shares in the last quarter. Morgan Stanley increased its stake in shares of Milestone Pharmaceuticals by 7.2% during the fourth quarter. Morgan Stanley now owns 1,330,188 shares of the company's stock valued at $5,268,000 after purchasing an additional 89,915 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $3,465,000. Finally, Barclays PLC increased its stake in shares of Milestone Pharmaceuticals by 18.6% during the fourth quarter. Barclays PLC now owns 641,353 shares of the company's stock valued at $2,540,000 after purchasing an additional 100,771 shares in the last quarter. 86.18% of the stock is currently owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.